COVID-19: EMA reviews corona drug

In addition to the development of corona vaccines, research also focuses on innovative drugs against SARS-CoV-2. The drug Evusheld, which was developed by AstraZeneca, is intended to protect infected people from a severe course of the corona virus.

Evusheld should be administered, among other things, in vaccination breakthroughs and infected risk patients in the first few days after infection or the onset of symptoms.

Corona drug Evusheld – that’s how it works

The drug consists of the two monoclonal antibodies tixagevimab and cilgavimab – these are antibodies that are modified on the basis of certain (virus) cells and defend themselves against the virus. The areas of application are mostly diagnostics and therapy, for example in cancer or as immunosuppression.  Monoclonal antibodies are also to be used for  COVID-19 .

These bind virus structures or block receptors on human cells. This is intended to prevent the  corona virus from entering  human cells. Tixagevimab and cilgavimab bind to different sites on the spike protein, blocking the virus from entering the cell.

Because different antibodies bind to different parts of the viral protein, using them together is more effective than using them alone.

EMA reviews corona drug in rolling review

In order to enable a faster approval process, the European Medicines Agency (EMA) reviews the first studies and results on corona drugs and vaccines in the run-up to the application for approval. This so-called rolling review process can thus speed up the official application for approval. In addition to Evusheld, the corona vaccines from Sinovac, Novavax and Sanofi as well as the Russian vaccine  Sputnik V are also  in the rolling process.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *